Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is a single center, phase II study, to evaluate the effectiveness and safety of
POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the neoadjuvant
therapy for patients with advanced/metastatic gastric cancer.